AMPLIFICATION OF c-MYC AND MLL GENES AS A MARKER OF CLONAL CELL PROGRESSION IN PATIENTS WITH MYELOID MALIGNANCY AND TRISOMY OF CHROMOSOMES 8 OR 11

被引:5
|
作者
Angelova, S. [1 ]
Jordanova, M. [2 ]
Spassov, B. [1 ]
Shivarov, V [1 ]
Simeonova, M. [3 ]
Christov, I [4 ]
Angelova, P. [3 ]
Alexandrova, K. [5 ]
Stoimenov, A. [1 ]
Nikolova, V [1 ]
Dimova, I [6 ]
Ganeva, P. [1 ]
Tzvetkov, N. [4 ]
Hadjiev, E. [5 ]
Toshkov, S. [1 ]
机构
[1] Natl Specialized Hosp Act Therapy Hematol Dis, Lab Cytogenet & Mol Biol, Sofia 1756, Bulgaria
[2] Children Hosp Hematol Dis, Sofia, Bulgaria
[3] Med Univ Hosp, Dept Med Genet, Pleven, Bulgaria
[4] Med Univ Hosp, Dept Hematol, Pleven, Bulgaria
[5] Med Univ Hosp, Dept Hematol, Sofia, Bulgaria
[6] Med Univ, Dept Med Genet, Sofia, Bulgaria
关键词
Gene amplification (amp); c-MYC; MLL genes; Acute myeloid leukemia (AML); Myelodysplastic syndromes (MDS); Myeloid malignancies; Trisomy chromosomes of 8 or 11; MYELODYSPLASTIC SYNDROME; MULTIPLE COPIES; LEUKEMIA; OVEREXPRESSION; ABNORMALITIES; DUPLICATION; SURVIVAL; TARGET; CANCER; TUMORS;
D O I
10.2478/v10034-011-0043-y
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Gene amplification (amp) is one of the basic mechanisms connected with overexpression of oncogenes. The c-MYC (located in 8q24) and MLL (located in 11q23) are the most often over represented genes that lead to a rapid proliferation of the affected cell clone in patients with myeloid neoplasms. Assessment of the level of amp c-MYC or amp MLL in the cases with trisomy 8 (+8) or trisomy 11 (+11) and myeloid malignances is necessary for a more precise estimation of the disease progression. A total of 26 patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) were included in the study: 18 with +8, six with +11 and two with complex karyotypes suspected of the partial trisomy. Routine cytogenetic analysis and fluorescent in situ hybridization ( FISH) were applied to indicate the chromosome alterations and genes amp in the bone marrow cells. Amp c-MYC was observed in 12 from 18 (66.7%) patients with +8. All the patients with +11 demonstrated a different level of amp MLL. In most of the cases with MDS (9/10), the coincidence of the +8 or +11 with amp c-MYC or amp MLL, respectively, leads to transformation to AML and/or short overall survival. Our data suggest that amp c-MYC and amp MLL develop in conformity with +8 and +11, especially in cases with progressive deviations in the karyotype as an aggressive expansion of an aberrant cell clone and appearance of additional chromosome anomalies.
引用
收藏
页码:17 / 23
页数:7
相关论文
共 41 条
  • [31] Establishment of a human herpes virus-8-negative malignant effusion lymphoma cell line (STR-428) carrying concurrent translocations of BCL2 and c-MYC genes
    Taira, Tamiko
    Nagasaki, Akitoshi
    Tomoyose, Takeaki
    Miyagi, Jun-ichi
    Kakazu, Naoki
    Makino, Shigeyoshi
    Shinjyo, Tetsuharu
    Taira, Naoya
    Masuda, Masato
    Takasu, Nobuyuki
    LEUKEMIA RESEARCH, 2007, 31 (09) : 1285 - 1292
  • [32] An indolent B-cell lymphoma with t(2;8)(p12;q24) abnormality and absence of C-MYC amplification and TP53 deletion.: A new variant?
    Potti, A
    Panwalkar, A
    Ingebretson, MC
    Tharapel, SA
    Goodell, M
    Dayton, MV
    Mehdi, SA
    CANCER GENETICS AND CYTOGENETICS, 2003, 144 (01) : 76 - 79
  • [33] Prostate cancer (ca) c-myc (8q24) amplification detected by fluorescence in situ hybridization (FISH) and MIB-I proliferation in needle biopsy (NBx) predict risk of clinical progression after radical prostatectomy (RP)
    Sebo, TJ
    Dora, CD
    Lan, F
    Kondo, Y
    Slezak, JM
    Bergstralh, EJ
    Jenkins, RB
    MODERN PATHOLOGY, 2005, 18 : 163A - 163A
  • [34] Prostate cancer (Ca) c-myc (8q24) amplification detected by fluorescence in situ hybridization (FISH) and MIB-I proliferation in needle biopsy (NBx) predict risk of clinical progression after radical prostatectomy (RP)
    Sebo, TJ
    Dora, CD
    Lan, F
    Kondo, Y
    Slezak, JM
    Bergstralh, EJ
    Jenkins, RB
    LABORATORY INVESTIGATION, 2005, 85 : 163A - 163A
  • [35] PROGESTINS BOTH STIMULATE AND INHIBIT BREAST-CANCER CELL-CYCLE PROGRESSION WHILE INCREASING EXPRESSION OF TRANSFORMING GROWTH FACTOR-ALPHA, EPIDERMAL GROWTH-FACTOR RECEPTOR, C-FOS, AND C-MYC GENES
    MUSGROVE, EA
    LEE, CSL
    SUTHERLAND, RL
    MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (10) : 5032 - 5043
  • [36] A T(8-14)(Q24-Q11) TRANSLOCATION IN A T-CELL LEUKEMIA (L1-ALL) WITH C-MYC AND TCR-ALPHA CHAIN LOCUS REARRANGEMENTS
    MATHIEUMAHUL, D
    SIGAUX, F
    ZHU, C
    BERNHEIM, A
    MAUCHAUFFE, M
    DANIEL, MT
    BERGER, R
    LARSEN, CJ
    INTERNATIONAL JOURNAL OF CANCER, 1986, 38 (06) : 835 - 840
  • [37] A novel human multiple myeloma-derived cell line, NCU-MM-1, carrying t(2;11)(p11;q23) and t(8;22)(q24;q11) chromosomal translocations with overexpression of c-myc protein
    Iida, S
    Hanamura, I
    Suzuki, T
    Kamiya, T
    Kato, M
    Hayami, Y
    Miura, K
    Harada, S
    Tsuboi, K
    Wakita, A
    Akano, Y
    Taniwaki, M
    Nitta, M
    Ueda, R
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2000, 72 (01) : 85 - 91
  • [38] Deletion of gene for surfactant protein a correlates with over-expression of EGFR, C-MYC, 6p11-q11 and polysomy 10/10q22-23 in non-small cell lung cancer (NSCLC). A FISH based study of 45 patients
    Katz, R. L.
    Zaidi, T.
    Fernandez, R.
    Khanna, A.
    Spitz, M.
    Vaporciyan, A.
    Caraway, N. P.
    LABORATORY INVESTIGATION, 2008, 88 : 344A - 344A
  • [39] Deletion of gene for surfactant protein a correlates with over-expression of EGFR, C-MYC, 6p11-q11 and polysomy 10/10q22-23 in non-small cell lung cancer (NSCLC). A FISH based study of 45 patients
    Katz, R. L.
    Zaidi, T.
    Fernandez, R.
    Khanna, A.
    Spitz, M.
    Vaporciyan, A.
    Caraway, N. P.
    MODERN PATHOLOGY, 2008, 21 : 344A - 344A
  • [40] The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single-centre data
    Misyurina, A. E.
    Kravchenko, S. K.
    Kovrigina, A. M.
    Magomedova, A. U.
    Plastinina, L., V
    Obukhova, T. N.
    Misyurin, A., V
    Misyurin, V. A.
    Grebenuk, L. A.
    Babaeva, F. E.
    Baryakh, E. A.
    Vorobiev, A., I
    TERAPEVTICHESKII ARKHIV, 2019, 91 (07) : 52 - 62